Combined Aerobic and Resistance Exercise for Patients With Type 2 Diabetes

Abstract

TYPE 2 DIABETES MELLITUS IS A MAJOR RISK FACTOR FOR excess morbidity and mortality. The excess vascular risk in type 2 diabetes is attributable both to hyperglycemia and to other metabolic disturbances associated with abdominal obesity, insulin resistance, and compensatory hyperinsulinemia. Sedentary lifestyle is also a major cardiovascular risk factor, and regular exercise attenuates the vascular risks associated with type 2 diabetes. Aerobic exercise refers to activities such as walking or jogging with continuous, repetitive movement of large muscle groups for at least 10 minutes at a time, whereas resistance exercise refers to activities such as weight lifting that use muscular strength to move a weight or work against a resistance load. Aerobic exercise for individuals with diabetes has been recommended for many decades, but the American Diabetes Association only began recommending resistance exercise in 2006. In this issue of JAMA, Church and colleagues report the results of the Health Benefits of Aerobic and Resistance Training in Individuals with Diabetes (HART-D) trial. This study provides important evidence on the effects of aerobic and resistance training on improving hemoglobin A1c (HbA1c) levels. In this trial, 262 previously sedentary patients with type 2 diabetes were randomized to a sedentary control group or to 1 of 3 exercise groups: aerobic exercise, resistance training, or a combination of both. Patients in the combined group performed smaller amounts of aerobic and resistance exercise than those in groups performing just one type of exercise so that the total amount of time devoted to exercise each week was similar among the 3 groups. The aerobic group performed 12 kcal/kg of body weight per week of aerobic exercise, equivalent to walking briskly at 4 mph for about 50 minutes per session 3 times a week. The resistance training group performed 2 to 3 sets of 10 to 12 repetitions of 9 exercises 3 times a week. The combined group performed 10 kcal/kg of body weight per week of aerobic exercise (equivalent to 42 minutes 3 times a week of walking at 4 mph, 83% of the amount done by the aerobic group) plus 1 set each of 9 exercises 2 times a week (less than a third of the resistance training volume performed by the resistance training group). No efforts were made to minimize changes in diet or medications. Only the combined training group achieved statistically significant reduction in absolute reduction in HbA1c in the HART-D trial compared with the control group (0.34%). The aerobic group had an absolute reduction of 0.24%; the resistance group, 0.16%. All groups had modest and similar decreases in waist circumference compared with the control group. In addition to the greatest HbA1c reduction, the combined training group also had the most decreases, and the least increases, in use of hypoglycemic medication. The findings of the HART-D trial are important for several reasons. First, the study duration was 9 months, making it longer than most exercise intervention trials involving patients with diabetes. Second, the study population was relatively large in number (n=262) and ethnically diverse, with almost 44% of participants being African American, and had a relatively high proportion of female participants (63%). Third, the total time spent exercising was roughly the same in the combined training group as in the other 2 singleexercise groups. Therefore, any difference between the combined exercise group and the other exercise groups can be confidently attributed to the combination of 2 types of exercise rather than the amount of time spent exercising. The HbA1c changes achieved in the HART-D trial were modest, perhaps because there was no effort to minimize medication changes. Participants whose HbA1c level did not improve with exercise were more likely to have their hypoglycemic therapy intensified, thus attenuating the difference in HbA1c that could be achieved between groups. It is likely that intergroup HbA1c differences in HART-D may have been greater if medication changes had been discouraged. The results are encouraging in that a significant incremental improvement in glycemic control was made in the HART-D combination group over and above that achieved through ongoing efforts by physicians and patients in both groups to optimize glycemic control with medications. Another possibility is that the higher proportion of women and